SCLN Profile
SciClone Pharmaceuticals, Inc. (SCLN) was a pharmaceutical company focused on developing and commercializing therapies to treat oncology, infectious, and cardiovascular diseases. The company was headquartered in Foster City, California, and was founded in 1989.
SciClone's primary products included Zadaxin (thymalfasin) and DC Bead. Zadaxin is an immune system booster used to treat hepatitis B and C, and certain types of cancer. DC Bead is a drug-eluting bead used in the treatment of liver cancer. In addition to these products, the company had a number of other products in development for a variety of indications.
In 2017, the company was acquired by a consortium led by GL Capital Group for $605 million. The acquisition was part of GL Capital's strategy to build a leading healthcare platform in China.
Prior to the acquisition, SciClone had faced a number of challenges, including regulatory and legal issues. In 2015, the company was fined by the U.S. Securities and Exchange Commission for violations of the Foreign Corrupt Practices Act. The company was also under investigation by the U.S. Department of Justice for similar issues.
Overall, SciClone Pharmaceuticals was a small pharmaceutical company focused on developing and commercializing therapies for a variety of diseases. While the company faced some challenges, its acquisition by GL Capital Group provided a path forward for continued growth and development.
|
